CincyTech — 2020 Investments
1 investments dated 2020 · listed companies and verified rows first · show all
Invirsa is a clinical-stage biopharmaceutical company developing DNA damage response therapeutics, with lead compound INV-102 in development for ocular conditions including sulfur mustard gas injury and diabetic dry eye disease.
BiotechDigital HealthMedical DevicesColumbus, US
Robert Shalwitz(Executive Officer, Director)inRachael Wingo(Executive Officer)
BoardWayne Embree(Director)Tim Willis(Director)Faith Voinovich(Director)inBethany George(Director)in
Board seatMichael Venerable· per SEC Form D
Co-investorsJobsOhio VenturesJumpstart VenturesOhio Innovation FundRev1 Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.